Clinical Trials Logo

Melanoma (Skin) clinical trials

View clinical trials related to Melanoma (Skin).

Filter by:

NCT ID: NCT00059800 Completed - Melanoma (Skin) Clinical Trials

Boron Neutron Capture Therapy in Treating Patients With Melanoma

Start date: May 2002
Phase: Phase 2
Study type: Interventional

RATIONALE: Boron neutron capture therapy may selectively kill tumor cells without harming normal tissue. PURPOSE: Phase II trial to study the effectiveness of boron neutron capture therapy in treating patients who have melanoma.

NCT ID: NCT00058279 Completed - Melanoma (Skin) Clinical Trials

Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma

Start date: February 2003
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Biological therapies, such as MDX-010, work in different ways to stimulate the immune system and stop tumor cells from growing. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Combining monoclonal antibody therapy with interleukin-2 may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining monoclonal antibody therapy with interleukin-2 in treating patients who have metastatic melanoma.

NCT ID: NCT00056134 Completed - Melanoma (Skin) Clinical Trials

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Start date: October 2002
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Vaccines made from a person's white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells. Biological therapies such as denileukin diftitox may be able to deliver cancer-killing substances directly to melanoma cells. Combining vaccine therapy with biological therapy may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining vaccine therapy with denileukin diftitox in treating patients who have stage III or stage IV melanoma.

NCT ID: NCT00054535 Completed - Melanoma (Skin) Clinical Trials

Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma

Start date: January 2003
Phase: Phase 2
Study type: Interventional

RATIONALE: Vaccines may make the body build an immune response that will kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy with interleukin-2 in treating patients who have metastatic melanoma.

NCT ID: NCT00053781 Completed - Melanoma (Skin) Clinical Trials

Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma

Start date: June 20, 2003
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of perifosine in treating patients who have metastatic or recurrent malignant melanoma.

NCT ID: NCT00053391 Completed - Melanoma (Skin) Clinical Trials

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Start date: October 2002
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Vaccines made from a person's white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have stage III or stage IV melanoma.

NCT ID: NCT00049530 Completed - Melanoma (Skin) Clinical Trials

PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma

Start date: January 13, 2004
Phase: Phase 2
Study type: Interventional

RATIONALE: Peginterferon (PEG-interferon) alfa-2b may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of PEG-interferon alfa-2b in treating patients who have stage IV melanoma.

NCT ID: NCT00049010 Completed - Melanoma (Skin) Clinical Trials

Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma

Start date: September 2002
Phase: N/A
Study type: Interventional

RATIONALE: Diagnostic procedures that analyze surgically-removed tumor tissue and lymph node samples may help doctors identify patients with melanoma who are at risk for developing metastatic cancer. PURPOSE: This clinical trial is studying tumor tissue and lymph node samples to see how well they work in predicting the development of metastatic cancer in patients with stage I or stage II melanoma.

NCT ID: NCT00045357 Completed - Melanoma (Skin) Clinical Trials

Biological Therapy in Treating Patients With Metastatic Melanoma

Start date: November 2001
Phase: Phase 1
Study type: Interventional

RATIONALE: Biological therapies use different ways to stimulate the immune system and stop tumor cells from growing. Treating a person's white blood cells in the laboratory and reinfusing them may cause a stronger immune response and kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of biological therapy in treating patients who have metastatic melanoma.

NCT ID: NCT00045149 Completed - Melanoma (Skin) Clinical Trials

Biological Therapy in Treating Patients With Metastatic Melanoma

Start date: October 2002
Phase: Phase 1
Study type: Interventional

RATIONALE: Biological therapies such as cellular adoptive immunotherapy use different ways to stimulate the immune system and stop cancer cells from growing. Treating a person's white blood cells in the laboratory and then reinfusing them may cause a stronger immune response and kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of biological therapy in treating patients who have metastatic melanoma.